IJCS | Volume 32, Nº2, March/April 2019

189 51. Sibley CT, Noureldin RA, Gai N, Nacif MS, Liu S, Turkbey EB, et al. T1 Mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy. Radiology. 2012;265(3):724-32. 52. Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015;36(4):244-51. 53. Piechnik SK, Ferreira VM, Dall'Armellina E, Cochlin LE, Greiser A, Neubauer S, et al. Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson. 2010 Nov 19;12:69. 54. Schelbert EB, Testa SM, Meier CG, CeyrollesWJ, Levenson JE, Blair AJ, et al. Myocardial extravascular extracellular volume fractionmeasurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus. J Cardiovasc Magn Reson. 2011 Mar 4;13:16. 55. Boynton SJ, Geske JB, Dispenzieri A, Syed IS, Hanson TJ, Grogan M, et al. LGE immunoglobulin light chain. JACC Cardiovasc Imaging. 2016;9(6):680-6. 56. Mohty D, Boulogne C, Magne J, Varroud-Vial N, Martin S, Ettaif H, et al. Prognostic value of left atrial function in systemic light-chain amyloidosis: a cardiac magnetic resonance study. Eur Heart J Cardiovasc Imaging. 2016;17(9):961-9. 57. Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2017;70(4):466-77. 58. Tuzovic M, Yang EH, Baas AS, Depasquale EC, Deng MC, Cruz D, et al. Cardiac amyloidosis: diagnosis and treatment strategies. Curr Oncol Rep. 2017;19(7):46. 59. Bellavia D, Pellikka PA, AbrahamTP, Al-Zahrani GB, Dispenzieri A, Oh JK, et al. 'Hypersynchronisation' by tissue velocity imaging in patients with cardiac amyloidosis. Heart. 2009;95(3):234-40. 60. Zumbo G, Sadeghi-Alavijeh O, Hawkins PN, Fontana M. New and developing therapies for AL amyloidosis. Expert Opin Pharmacother. 2017;18(2):139-49. 61. Adams D, Gonzalez-DuarteA, O,RiordanWD, YangCC, UedaM, Kristen AV, et al. Patisiran, an a RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11-21. 62. BensonMD, Waddington-CruzM, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22-31. 63. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. NEngl JMed. 2018;379(1):1007-16. Ribeiro et al. CMR and amyloidosis Int J Cardiovasc Sci. 2019;32(2)177-189 Review Article This is an open-access article distributed under the terms of the Creative Commons Attribution License